an error.
delivered every two weeks (dose-dense EC-P) compared to every 3 weeks, the guideline adaptation should have included the dose-dense EC-P regimen, as provided below, in the list of acceptable adjuvant chemotherapy regimens for patients with higher-risk early breast cancer.
Dose-dense epirubicin 90 mg/m 2 , cyclophosphamide 600 mg/m 2 every 2 weeks 4 cycles → paclitaxel 175 mg/m 2 every 2 weeks for 4 cycles. The online version has been corrected in departure from the print. The authors regret the omission. His affiliation is at the St. Luke's-Roosevelt Medical Center.
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